secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-092535
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics reports Q4 net loss $38.7M, cash $343M; vopimetostat pivotal study on track for 2026
--------------------------------------------------------------------------------

- Net loss $38.7M for Q4 2025 ($0.29/share) vs $30.8M for Q4 2024; FY2025 net loss $101.6M vs $130.3M.
- Cash, equivalents and marketable securities $343.1M as of Dec 31, 2025; runway into 2028.
- Collaboration revenue $62.4M for FY2025, including full recognition of remaining Gilead deferred revenue after collaboration truncation.
- Vopimetostat pivotal study in 2L MTAP-del pancreatic cancer to start in 2026; initial phase 1/2 combo data with RAS(ON) inhibitors expected in 2026.
- Signed clinical supply agreement with Erasca for vopimetostat + pan-RAS molecular glue ERAS-0015; CEO succeeded by Malte Peters in January 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/0001193125-26-092535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/tngx-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-092535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer